Details

Autor(en) / Beteiligte

• Levis, Mark J
• Hamadani, Mehdi
• Logan, Brent
• Jones, Richard J
• Singh, Anurag K
• Litzow, Mark
• Wingard, John R
• Papadopoulos, Esperanza B
• Perl, Alexander E
• Soiffer, Robert J
• Ustun, Celalettin
• Ueda Oshima, Masumi
• Uy, Geoffrey L
• Waller, Edmund K
• Vasu, Sumithra
• Solh, Melhem
• Mishra, Asmita
• Muffly, Lori
• Kim, Hee-Je
• Mikesch, Jan-Henrik
• Najima, Yuho
• Onozawa, Masahiro
• Thomson, Kirsty
• Nagler, Arnon
• Wei, Andrew H
• Marcucci, Guido
• Geller, Nancy L
• Hasabou, Nahla
• Delgado, David
• Rosales, Matt
• Hill, Jason
• Gill, Stanley C
• Nuthethi, Rishita
• King, Denise
• Wittsack, Heather
• Mendizabal, Adam
• Devine, Steven M
• Horowitz, Mary M
• Chen, Yi-Bin

Titel

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3

Ist Teil von

• Journal of clinical oncology, 2024-05, Vol.42 (15), p.1766-1775

Ort / Verlag

United States

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of ( ) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. Adults with AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. Three hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided = .0518). However, 50.5% of participants had MRD detectable pre- or post-HCT, and, in a prespecified subgroup analysis, gilteritinib was beneficial in this population (HR, 0.515 [95% CI, 0.316 to 0.838]; = .0065). Those without detectable MRD showed no benefit (HR, 1.213 [95% CI, 0.616 to 2.387]; = .575). Although the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.